TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01512433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ture acupuncture
Description: Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling.
Study: NCT04857853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Without Rest Break
Description: Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise With Rest Break
Description: Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest Break
Description: Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises.
Study: NCT03793959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04543812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Description: Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
Study: NCT03153813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsaicin 8% patches (Qutenza)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patches
Study: NCT03040245

Intervention type: BEHAVIORAL
Intervention: Whiplash book

Intervention type: BEHAVIORAL
Intervention: Whiplash book
Study: NCT03715868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-milked derived protein source formula diet
Description: Formula diet based on a non-milked derived protein source
Study: NCT01062269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: Cholestyramine 4 grams one time dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: Cholestyramine 12 grams one dose, one day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tang
Description: Tang one dose one day
Study: NCT04606147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block
Description: The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
Study: NCT01266161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg ER
Description: One 600 mg caplet dosed at 0, 12, 24 and 36 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo caplet dosed at times 0, 12, 24 and 36 hours
Study: NCT04592081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dextenza 0.4Mg Ophthalmic Insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dextenza 0.4Mg Ophthalmic Insert
Study: NCT02775305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frail
Description: Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques.
Study: NCT00915577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: 30mcg, IM once-a-week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use autoinjector
Description: Single-use autoinjector with Avonex 30mcg pre-filled syringe
Study: NCT01390142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Deflated blood pressure cuff placed on upper arm for 30min

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPer
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIPer + IPost
Description: Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
Study: NCT00184379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Structured disorder-related educational program for relatives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Structured disorder-related educational program for relatives
Study: NCT02991586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Group of families
Study: NCT03995342

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin 15 grams after dissolution by mouth， every morning for three months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
Study: NCT02682940

Intervention type: DEVICE
Group type: OTHER
Intervention: Vigilant Diabetes Management Application
Description: Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
Study: NCT02409446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
Study: NCT02365103

Intervention type: OTHER
Group type: OTHER
Intervention: Test meal I (given with water)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing

Intervention type: OTHER
Group type: OTHER
Intervention: Test meal II (simultaneously with tea)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing

Intervention type: OTHER
Group type: OTHER
Intervention: Test meal III (1 hour after test meal)
Description: 4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing

Intervention type: OTHER
Group type: OTHER
Intervention: Reference iron dose
Description: 3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
Study: NCT01898715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Study: NCT04383951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary consult for participants in the ketogenic diet arm
Description: An initial consultation with the providers of medically supervised weight loss clinic will be arranged. Participants in the ketogenic diet group will be educated on the concepts of the diet and will be provided with recipes to be utilized at home that adhere to this diet. In addition to the initial consultation, participants in this arm receive additional consultations with these providers with a frequency as determined by the provider.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dietary consult for participants in the standard of care arm
Description: For participants in the standard of care arm, an initial consultation with the providers of medically supervised weight loss clinic will be arranged and the discussion will center around portion control using a balanced diet. Participants will receive only one additional consultation with the provider 16 weeks later just prior to the conclusion of the study.
Study: NCT01078922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
Study: NCT02271022

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study: NCT03190512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychological measurements
Description: Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological measurements
Description: Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
Study: NCT02888379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for TOP1288)
Study: NCT03639727

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid aerosol bronchial challenge
Description: Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol aerosol bronchial challenge
Description: Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
Study: NCT00541905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
Study: NCT02903303

Intervention type: OTHER
Group type: OTHER
Intervention: Hypnosis
Description: It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning.
Study: NCT04238533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eADAPT training
Description: eADAPT training for myoelectric prosthesis users is the comparator training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: Conventional training with Myoboy has been the only training available to users.
Study: NCT01774305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
Study: NCT00136370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Birth canal wipe

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sterile water external genital wipe
Study: NCT01408745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sternumfix
Description: sternotomy closure with Sternumfix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steel wire
Description: sternotomy closure with steel wire
Study: NCT00603083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine, Ketorolac and Adrenalin
Description: The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
Study: NCT00953316

Intervention type: OTHER
Intervention: Measure infant's jaw, record all information about car seat testing, and administer questionnaires.
Description: Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
Study: NCT03478137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP intervention
Description: Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
Study: NCT01341847

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water method colonoscopy
Description: This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: air method colonoscopy
Description: This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
Study: NCT02689453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 plus
Description: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15 plus
Description: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
Study: NCT02394249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity regime
Description: Information already included in arm descriptions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity regime
Description: Information already included in arm descriptions
Study: NCT03327831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Topical application followed by activation by ambient sunlight
Study: NCT01807429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-midazolam
Description: Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 0.05 mg/kg
Study: NCT00927901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 400 μg
Description: Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 400 μg
Description: Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 400 μg
Description: Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate 400 μg
Description: Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate 400 μg
Description: Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate 400 μg
Description: Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate 400 μg
Description: Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate 400 μg
Description: Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol xinafoate 400 μg
Description: Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol xinafoate 400 μg
Description: Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
Study: NCT02963519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VistaCare®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dressings